Spots Global Cancer Trial Database for Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma

Official Title: Prospective Observational Study of Imaging-based Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastomas

Study ID: NCT04143425

Conditions

Adult Glioblastoma

Magnetic Resonance Imaging

Bevacizimab

Interventions

3-Tesla conventional magnetic resonance imaging

Advanced imaging without contrast use

Dynamic susceptibility contrast-weighted imaging

Study Description

Brief Summary: This study aims to evaluate whether pre-treatment MRI can be used to predict treatment response for anti-angiogenic treatment in glioblastomas.

Detailed Description: Although overall the effects on prolonging survival in bevacizumab-treated patients is modest at best, it is still unclear whether there is not a more substantial positive effect in a subset of patients, potentially identifiable by imaging markers. Allowing for prediction of good or bad responder from anti-angiogenic therapy prior to treatment completion is important to select patients most likely to benefit from anti-angiogenic treatment. This is a prospective observational study and no active comparator will be used. Study participants include adult patients with recurrent glioblastoma. We hypothesized that quantifying changes in multi-modal advanced MR imaging techniques would allow early treatment response and long-term prediction in glioblastomas.